BlackRock backs UK life sciences firm in latest PE round

BlackRock, the US asset manager, has taken part in a $75m Series 'C' financing for Immunocore, a UK life sciences company that works in developing treatments that use the body’s T-cell receptors to fight cancer and other diseases.

Read Previous

Checkout.com Triples Valuation to $15bn with $450m Series C Fundraise, Accelerating Global Expansion

Read Next

Dr Martens takes first step towards £1bn-plus IPO

Most Popular